ReviewMedicina (Kaunas, Lithuania)2026
Kidney Biopsy and Prognosis in Lupus Nephritis: Histological Predictors of Renal Outcome-A Narrative Review.
Review in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The kidney biopsy is the cornerstone of prognostication in lupus nephritis, yet which features predict renal outcome-and which kind-remains incompletely defined. This narrative review relates eight histological axes to two families of renal outcome defined a priori: soft outcomes (renal flare/relapse and response/remission) and hard outcomes (doubling of serum creatinine, sustained decline in estimated glomerular filtration rate, and end-stage kidney disease; death is considered a competing, patient-level outcome). The axes span the ISN/RPS classification and its 2018 revision, individual glomerular and tubulointerstitial lesions, NIH activity and chronicity indices, lupus podocytopathy, lupus vasculopathy, antiphospholipid-antibody nephropathy, thrombotic microangiopathy and repeat biopsy. Across them, a consistent asymmetry emerges, although it is often not reproducible between studies. Chronicity-especially tubulointerstitial damage-predicts hard outcomes, whereas the activity index as a whole predicts response and flare. Cellular crescents and fibrinoid necrosis, active lesions that can signal hard outcomes, are the exceptions. Whether chronicity adds to baseline kidney function remains unsettled. Several prognostically important entities lie outside the proliferative classification; immune-deposit burden is largely diagnostic; and repeat histology adds information beyond the baseline biopsy. A recurring caveat is the therapeutic era, which modifies the very lesions scored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.